Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin after ASCT in B-cell and Hodgkin Lymphoma
NCT04491370Phase 2Recruiting
- Sponsor
- New York Medical College
- Start
- Aug 2021
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin in B cell lymphoma, Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), sponsored by New York Medical College. Started Aug 2021; status: recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
B cell lymphomaBurkitt lymphoma (BL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04491370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04491370.